Stay updated on bb21217 Efficacy in Myeloma Clinical Trial

Sign up to get notified when there's something new on the bb21217 Efficacy in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the bb21217 Efficacy in Myeloma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 1 clinical trial for bb21217, an Anti-BCMA CAR T Cell Drug Product, in adults with relapsed/refractory multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:20.000Z thumbnail image
  6. Check
    19 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying inclusion and exclusion criteria such as age, health status, and prior treatments. Previously, this section only indicated that no information was provided.
    Difference
    22%
    Check dated 2024-05-22T21:13:42.000Z thumbnail image
  7. Check
    41 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:18:39.000Z thumbnail image

Stay in the know with updates to bb21217 Efficacy in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the bb21217 Efficacy in Myeloma Clinical Trial page.